SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending due to the FDA's recent approval of its oral Wegovy pill, marking a significant milestone as the first GLP-1-based oral therapy for weight management. The community is buzzing about this "game changer," highlighting its convenience over injections and Novo Nordisk's first-mover advantage against competitors like Eli Lilly, with many anticipating a substantial rebound for the stock.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is experiencing a significant surge, primarily driven by recent high-grade silver drill results from its Vortex system. This has ignited a strong rally, further fueled by rising precious metal prices and widespread speculation about a short squeeze. The community is actively discussing major investor Eric Sprott's continued substantial investments and the long-term potential of the company's vast silver and gold deposits.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing a significant rally, fueled by tightening global supply, particularly from imminent Chinese export restrictions, and soaring industrial demand from sectors like EV batteries and solar. The community is buzzing about a potential silver squeeze, highlighting its historical undervaluation and anticipating substantial price discovery, while some voices warn of an extended, overbought market.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. (SOC) is currently trending as federal regulators have approved the restart plan for its Las Flores Pipeline system, shifting regulatory authority from California to federal oversight. This development has ignited significant community discussion regarding a potential short squeeze and a major upside move, with many seeing it as a critical de-risking event for the company's California offshore oil assets, despite some lingering concerns about its financial standing.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as the market eagerly anticipates a pivotal FDA decision on narsoplimab for TA-TMA, with its PDUFA date approaching and speculation swirling about an early holiday announcement. The community is highly optimistic for significant upside and a potential short squeeze, fueled by the recent, de-risking Novo Nordisk deal that eliminated debt and validated the company's financial strength. This potential approval for a first-in-class, life-saving drug is viewed as a transformative event, with investors actively discussing its long-term value and buyout prospects.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is trending due to recent bullish commentary from Citron Research and Infleqtion's strategic partnerships, including collaborations for high-precision quantum timing in GPS-denied environments and defense applications. The community is actively discussing Infleqtion's real-world applications and strong revenue pipeline, positioning it as a significantly undervalued leader compared to other quantum pure-plays. Anticipation is building for the upcoming merger, which is expected to unlock substantial institutional investment and elevate Infleqtion's profile in the critical quantum technology sector.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending due to a series of recent strategic partnerships and teaming agreements focused on its thin-film solar technology for space, defense, and drone applications. While bulls are anticipating a potential short squeeze and significant contract upside from these ventures, a skeptical segment of the community remains cautious, citing the company's historical dilution and ongoing financial challenges despite these new collaborations.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is a top trending stock as the "SpaceMob" eagerly awaits the launch of its BlueBird 6 satellite, a crucial event for advancing global direct-to-device cellular broadband. While bulls are looking for this "infrastructure going live" moment to validate ASTS's long-term potential, skeptical investors debate its current valuation and predict a "sell the news" reaction, fueling intense community discussion. This pivotal launch is seen as a key step in the company's accelerated campaign within the rapidly evolving space sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending significantly higher, with community discussion centered on its record-breaking price levels. This ascent is largely attributed to increasing global geopolitical uncertainty, central bank buying, and anticipation of looser monetary policies, prompting some to view gold as a crucial safe-haven asset amidst broader market concerns and underperforming cryptocurrencies. However, conversations also include caution regarding potential market manipulation and the sustainability of its rapid climb, with some expecting a notable pullback.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on September 3, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings (VWAV) is trending following a recently issued U.S. patent for its real-time RF movement and position imaging technology, further solidifying its AI and defense capabilities. The community is actively discussing this patent win, alongside the company's recent acquisition of Solar Drone, believing these catalysts could drive significant volume and spark a short squeeze for the low-float AI/Defense stock, drawing comparisons to successful industry peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Purchases $16,000.00 in Stock

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report) CFO Mark Rosenblum purchased 20,000 shares of the company's stock in a transaction on Thursday, November 20th. The stock was purchased...

Penny Stocks To Follow Now - November 12th

Leap Therapeutics, Bitfarms, MSP Recovery, Strive, Salarius Pharmaceuticals, HIVE Digital Technologies, and Beyond Meat are the seven Penny stocks to watch today, according to MarketBeat's stock...

Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?

Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement. read more...

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering PR Newswire HOUSTON, Nov...

Salarius Pharmaceuticals’ stock rose 5% after-hours on Monday after announcing it had regained full compliance with all Nasdaq listing requirements, removing the main hurdle to its planned merger with Decoy Therapeutics.The company said Nasdaq informed Salarius on Oct. 10 that it met the equity standard requirement, following an earlier notice in September that it had regained compliance with the minimum bid price rule.Nasdaq notified the company that it will remain under a one-year Mandatory Panel Monitor period through October 2026, during which any violation of equity standards could lead to a delisting notice and hearing process.The merger with Decoy Therapeutics, first announced in January and amended in September, will see Decoy merge into a unit of Salarius, with the combined company operating under the name Decoy Therapeutics. The deal is intended to accelerate the development of peptide conjugate therapeutics through Decoy’s IMP3ACT platform and integrate Salarius’ SP-3164 degrader program.Once complete, the combined company will be led by Decoy’s co-founders, Frederick Pierce and Barbara Hibner, alongside key executives from both firms. Over the next year, Decoy plans to push its lead antiviral drug for coronaviruses closer to FDA review, while also working on new treatments for flu, COVID-19, RSV, and certain gastrointestinal cancers.Salarius, meanwhile, is supporting a clinical study at MD Anderson Cancer Center that’s testing its main drug, seclidemstat, as a possible treatment for serious blood cancers with few existing options.On Stocktwits, retail sentiment for Salarius was ‘bullish’ amid a 5,000% surge in 24-hour message volume.One user said they had added to their Salarius position, citing the company’s low float, full Nasdaq compliance, and solid cash runway.&nbsp;<stembedurl>https://stocktwits.com/Rick2058/message/632179803</stembedurl>Another user noted they felt confident about the stock’s setup, pointing to its low price, small float, and high cost-to-borrow rate, adding that any positive news could send it soaring.<stembedurl>https://stocktwits.com/The_TendieMan_Cometh/message/632144546</stembedurl><a href="https://stocktwits.com/symbol/SLRX">Salarius’ stock</a> has declined 86% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Salarius’ stock (SLRX) has declined 86% so far in 2025. (Photo credit: Getty Images)

Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger —  Retail Bulls Bet On Breakout

The company’s move removes the last major hurdle to completing its merger with Decoy Therapeutics, a deal aimed at advancing antiviral and cancer drug programs through Decoy’s IMP3ACT platform.

Equity

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

SLRX
Salarius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results:

Historical Earnings

Latest SLRX News

SLRXSalarius Pharmaceuticals Inc